Skip to content

Precision Fluid Therapy for Septic Shock Based on Immuno-Endothelial Monitoring: A Real-World Study

A Real-World Study of Precision Fluid Therapy Strategy for Septic Shock Based on Immuno-Endothelial Dynamic Monitoring

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600127791
Enrollment
Unknown
Registered
2026-07-07
Start date
2026-08-01
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic Shock

Interventions

Control Group:Standard Fluid Therapy Strategy
Intervention Group:Precision Fluid Therapy Strategy
Observation Group:None

Sponsors

Ruijin-Hainan Hospital Shanghai Jiao Tong University School of Medicine (Hainan Boao Research Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for septic shock according to Sepsis-3 definition; 2. Aged >= 18 years; 3. The patient or their legal representative has voluntarily signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Aged < 18 years, or pregnant or lactating women; 2. Primary immune deficiency disorders; active autoimmune diseases receiving immunosuppressive therapy; HIV infection with CD4 count < 200/µL; active hematologic malignancies; 3. Long-term immunosuppressive status, including long-term use of glucocorticoids or other potent immunosuppressants (e.g., cyclosporine, tacrolimus, cyclophosphamide) before ICU admission, or post-organ transplant status; 4. End-stage disease with expected survival < 24 hours, or decision to pursue palliative care; 5. Receipt of experimental therapies that may significantly interfere with immune function assessment prior to enrollment; 6. Presence of other severe comorbidities: Child-Pugh Class C cirrhosis, end-stage renal disease requiring dialysis, or severe cardiac dysfunction (NYHA Class IV);

Design outcomes

Primary

MeasureTime frame
28-Day All-Cause Mortality;

Secondary

MeasureTime frame
Duration of Vasopressor Use;Duration of Renal Replacement Therapy;Total Hospital Cost;Cost-Effectiveness Ratio;Incidence of Acute Kidney Injury;ICU Length of Stay;Incidence of Ventilator-Associated Pneumonia;Duration of Mechanical Ventilation;

Countries

China

Contacts

Public ContactLiu Yiyun

Ruijin-Hainan Hospital Shanghai Jiao Tong University School of Medicine (Hainan Boao Research Hospital)

ps_l@hotmail.com+86 898 6262 0917

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026